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BACKGROUND: We tested the accuracy of immunocytochemistry (ICC) for minichromosome maintenance protein-2 (MCM-2) in
diagnosing bladder cancer, using cells retrieved from urine.
METHODS: Adequate samples were obtained from 497 patients, the majority presenting with gross haematuria (GH) or undergoing
cystoscopic surveillance (CS) following previous bladder cancer. We performed an initial study of 313 patients, followed by a
validation study of 184 patients. In all cases, presence/absence of bladder cancer was established by cystoscopy/biopsy.
RESULTS: In the initial study, receiver operator characteristic analysis showed an area under the curve of 0.820 (Po0.0005) for the GH
group and 0.821 (Po0.01) for the CS group. Optimal sensitivity/specificity were provided by threshold values of 50þ MCM-2-
positive cells in GH samples and 200þ cells in CS samples, based on a minimum total cell number of 5000. Applying these
thresholds to the validation data set gave 81.3% sensitivity, 76.0% specificity and 92.7% negative predictive value (NPV) in GH and
63.2% sensitivity, 89.9% specificity and 89.9% NPV in CS. Minichromosome maintenance protein-2 ICC provided clinically relevant
improvements over urine cytology, with greater sensitivity in GH and greater specificity in CS (P¼ 0.05).
CONCLUSIONS: Minichromosome maintenance protein-2 ICC is a reproducible and accurate test that is suitable for both GH and CS
patient groups.
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Most patients with bladder cancer present with either gross
haematuria (GH) or microscopic haematuria (MH) (Rodgers et al,
2006). The majority of bladder cancers are superficial, non-muscle-
invasive tumours with a good prognosis. However, over two thirds
of such cases recur, of which 10–30% progress to muscle-invasive
disease (Heney et al, 1983; Rubben et al, 1988; Pagano et al, 1991;
Prout et al, 1992). This has led to the development of surveillance
programmes, in order to limit the morbidity and mortality
associated with recurrent disease. Currently accepted investigations
for surveillance include cystoscopy with urinary cytology (Halling
and Kipp, 2008), as well as imaging of the upper urinary tract.
The reported sensitivity of urine cytology for high-grade bladder
cancer and carcinoma in situ (CIS) varies from 38–84%, with a
reported specificity of 83–99.7% (Lotan and Roehrborn, 2003).
Although it is cheap and non-invasive, the lowest sensitivity of
cytology is in detecting the commonest bladder cancers, which
are superficial low-grade tumours (Karakiewicz et al, 2006).
Cystoscopy is the gold standard investigation but has false-
negative rates of 10—40%, either from operator error or from
small areas of CIS, which may be difficult to detect (Herr, 1999; van
der Poel and Debruyne, 2001; Hwang et al, 2011). Furthermore,
cystoscopy is associated with potential side effects and may cause
discomfort and distress to the patient. Current follow-up protocols
after the initial diagnosis of bladder cancer typically include
regular flexible cystoscopy and urine cytology, performed as often
as every three months for 1–3 years and every 6 months for 2–3
years thereafter, depending on tumour characteristics. Annual
follow-up is often then undertaken, assuming no recurrence of
tumour.
In view of the clinical burden and cost associated with
surveillance of non-muscle-invasive bladder cancer, there is an
increasing drive to identify more reliable urinary biomarkers.
Non-invasive biomarkers could be useful both for screening high-
risk populations and monitoring patients with a history of bladder
cancer. This may help identify early recurrence and hence prevent
disease progression. Thus, a reliable urine marker has the potential
to replace or complement cystoscopy for both the initial diagnosis
of bladder cancer and for future surveillance.
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At least 14 such biomarkers have so far been described, 6 of
which have received approval from the United States Food and
Drug Administration (Herman et al, 2008). However, none meets
all the criteria of an ideal tumour biomarker. Indeed, non-invasive
tumour markers in general have sensitivity for bladder cancer
equal to or only slightly greater than that of cytology, even in high-
grade cancers.
Since the late 1990s, there has been interest in developing
screening tests for epithelial cancers, based on minichromosome
maintenance (MCM) proteins as biomarkers (Williams et al, 1998;
Freeman et al, 1999; Stoeber et al, 1999; Davies et al, 2002; Sirieix
et al, 2003; Baldwin et al, 2003; Chatrath et al, 2003).
Minichromosome maintenance proteins 2–7 are essential for
DNA replication in all eukaryotic cells and for restricting
replication to once per cell cycle (Kearsey and Labib, 1998;
Gonzalez et al, 2005). These proteins, which are abundant
throughout the cell cycle (Kearsey et al, 1996; Maiorano et al,
1996), are downregulated following cell cycle exit by quiescence,
differentiation or senescence (Musahl et al, 1998; Madine et al,
2000; Stoeber et al, 2001).
The application of MCMs to detecting bladder cancer is based
on the fact that most cells in the human body, including urothelial
cells, are not cycling and exist in a state of quiescence (G0 phase).
Although MCMs are normally restricted to the basal proliferative
compartments of epithelia, ectopic expression is a characteristic
feature of malignancy and pre-malignancy. Indeed, MCM expres-
sion is often seen in all epithelial layers, including the superficial
cells (Gonzalez et al, 2005; Scarpini et al, 2008). This is the case for
bladder cancer, where a high frequency of MCM-positive cells
correlates with adverse clinical outcome (Korkolopoulou et al,
2005).
In the bladder, surface cells are exfoliated into the urine.
Immunocytochemical staining for MCMs should therefore allow
discrimination between immuno-positive abnormal cells and their
immuno-negative normal counterparts. Early work suggested that
MCMs could be detected using liquid-phase assays performed on
homogenised urinary sediments (Stoeber et al, 1999) and the
clinical performance of this approach was subsequently assessed
using 353 urine samples (Stoeber et al, 2002). An alternative
approach, which may find greater favour among practising
cytopathologists, is to detect MCMs in urine-derived epithelial
cells by immunocytochemistry (ICC). This commonly-used
technique preserves cell morphology and allows cytological
verification of cellular abnormalities, based on the haematoxylin
counterstain.
Here, we report the findings of a study of bladder cancer
detection using immunocytochemical staining for MCM-2 in cells
retrieved from urine. We studied 497 patients referred for investi-
gation of possible bladder cancer, either presenting with GH or
MH, together with patients with a known history of bladder cancer
who were on cystoscopic surveillance (CS) as part of their routine
clinical care. Our data show that MCM-2 ICC is a reproducible and
accurate diagnostic test that warrants larger-scale application.
MATERIALS AND METHODS
Study subjects
Patients attending urology clinics at two centres in the UK were
recruited into the study. The first was Aberdeen Royal Infirmary,
where the initial phase of the study evaluating the practicality of
using urinary MCM-2 ICC for detecting bladder cancer was carried
out. The second was Addenbrooke’s Hospital, Cambridge, where
we validated and extended the findings of the Aberdeen study. All
patients gave written consent before being recruited. Local
Research Ethics Committee approval was granted for each
institution (Aberdeen Ref. 07/SO802/136; Cambridge Ref. 03/018).
All urine samples used to analyse test accuracy were from
patients in whom the presence or absence of bladder cancer was
ascertained by cystoscopy and biopsy. In all cases, the relevant
tissue diagnosis was made by a member of the team of consultant
urological histopathologists at the participating centre.
Pilot phase (Aberdeen)
Fifty-six of 74 patients with established bladder cancer who were
invited, agreed to participate in the pilot work. A total of 154 urine
samples were collected from these 56 participants. The pilot work
was aimed at optimising: (i) timing of urine sample collection;
(ii) storage and processing conditions for generating liquid-based
cytology (LBC) samples; (iii) urine sample volume; and (iv) slide
storage conditions that preserved intact bladder epithelial cells
over 3 months.
The work confirmed that early morning urine samples were of
poor quality and that the best time for obtaining samples was
between 1100 and 1600 hours (data not shown). All samples
required processing within 4 h of voiding. Under these conditions,
50ml urine aliquots from whole-volume urine voids produced
adequate numbers of bladder epithelial cells in all samples
collected (data not shown). Cells remained intact for over 3
months on LBC slides sprayed with Surgipath (Surgipath Medical
Inc., Richmond, IL, USA) and stored in the dark at 4 1C (data not
shown).
Initial study (Aberdeen)
In the initial study at Aberdeen Royal Infirmary, urine samples
(regardless of adequacy) were obtained from a total of 317 patients,
recruited from the GH (170 patients) or follow-up CS clinics (147
patients). There were 26 individuals with bladder cancer in these
patient groups. In addition, 51 patients presenting with MH were
investigated (none with bladder cancer). A further 50 urines were
collected from normal control subjects with no clinical evidence of
urinary tract pathology. Further details are given in Table 1. No
positive selection criteria were applied, although patients with
other urinary tract pathology, catheter in situ and evidence of
secondary spread of bladder cancer were excluded. A fresh whole-
volume urine void was collected from each participant. Samples
were transferred to the cytopathology laboratory for analysis
within 4 h from the time of void.
Validation study (Cambridge)
In total, urine samples (regardless of adequacy) were obtained
from 249 patients at the Urology Outpatient Clinic, Addenbrooke’s
Hospital, Cambridge. No positive selection criteria were applied,
with exclusion criteria being as for the initial study (Aberdeen). Of
the 249 patients, 89 presented with GH, 44 with MH and 116 were
undergoing CS for bladder cancer. Full details are given in Table 2.
All samples were prepared and stained using the methodology
determined from the Aberdeen studies (see below). Two LBC slides
were made, one for routine Papanicolaou (PAP) staining using the
conventional method and a second for MCM-2 ICC, which was
performed at a separate commercial laboratory (Quest Labora-
tories, London, UK). The immuno-stained slides, together with the
PAP-stained slide for each patient, were thereafter transferred to
the Manchester Royal Infirmary and reviewed independently by
two senior cytopathologists (DR and MP).
Preparation of LBC slides from urine samples
Specimens were decanted into 50ml Falcon tubes at the
cytopathology laboratory and centrifuged at 2500 r.p.m. for
10min. Two cell pellets were pooled by washing with Cytolyt
(Hologic UK, Crawley, UK). The pooled sample was then
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re-centrifuged and the cell pellet re-suspended and split equally
between two PreservCyt vials (Hologic, UK), one for conventional
PAP staining and one for MCM-2 ICC. Thin layer slides were
prepared using a standard Thinprep 2000 processor (Hologic UK).
Papanicolaou staining was undertaken following the standard
clinical diagnostic method and the slides assessed for cellularity
and malignancy by the lead consultant cytopathologists (MM, DR,
MP). Slides for ICC assessment were spray fixed with Surgipath
(Surgipath Medical Inc.) and stored at 4 1C until stained.
Immunocytochemical staining for MCM-2
Immunocytochemistry was performed using a standard biotin-free
Dako REAL Envision detection system (K5007) staining method,
using 3,30-diaminobenzidine (DAB) as the chromogen, on an
automated Dako Flat Bed-Stainer (Dako, Ely, UK).
The thin layer slides were incubated in 50% ethanol for 5min
then rinsed in water before antigen retrieval. The antigen retrieval
step consisted of heating the slides in EDTA buffer (pH 7.8) at
Table 1 Summary of patient details and results for the initial study
(Aberdeen)
GH CS MH Control
Median age 64 73 61.5 34
(Range) (19–90) (32–90) (21–87) (20–64)
Male 115 108 21 21
(%) (68) (74) (41) (42)
Female 55 39 30 29
(%) (32) (26) (59) (58)
Total 170 147 51 50
(%) (100) (100) (100) (100)
No of bladder cancer 21 5 0 0
(%) (17.9) (4.5)
MCM-2
No of adequate samples 117 112 42 42
(%) (68.8) (76.2) (82.4) (84.0)
Sensitivity 85.7% 60.0%
(95% CI) (63.7, 97.0) (14.6, 94.7)
Specificity 52.1% 79.4%
(95% CI) (41.6, 62.4) (70.5, 86.6)
NPV 94.3% 97.7%
Cytology
No of adequate samples 117 113
(%) (68.8) (76.9)
Sensitivity 71.4% 40%
(95% CI) (47.8, 88.7) (5.3, 85.3)
Specificity 88.5%* 72.2%
(95% CI) (80.4, 94.1) (62.8, 80.4)
NPV 96.6% 98.7%
MCM-2/cytology
No of adequate samples 118 113
(%) (69.4) (76.9)
Sensitivity 86.4% 60.0%
(95% CI) (65.1, 97.1) (14.7, 94.7)
Specificity 52.1% 76.9%
(95% CI) (41.6, 62.4) (67.8, 84.4)
NPV 94.3% 97.6%
Abbreviations: CI, confidence interval; CS, cystoscopic surveillance; GH, gross
haematuria; MCM-2, minichromosome maintenance protein-2; MH, microscopic
haematuria; NPV, negative predictive value. The threshold number of MCM-2-
positive cells was 50 for the GH group and 200 for the CS group. For all adequate
samples, the presence or absence of bladder cancer was established by cystoscopy/
biopsy. The combined MCM-2/cytology test was considered positive if either of the
individual tests was positive. *Po0.005 for MCM-2 testing vs urine cytology.
Table 2 Summary of patient details and results for the validation study
(Cambridge)
GH CS MH
Median age 65 71 60
(Range) (22–87) (48–89) (37–82)
Male 62 91 17
(%) (70) (78) (39)
Female 27 25 27
(%) (30) (22) (61)
Total 89 116 44
(%) (100) (100) (100)
No of bladder cancer 16 19 0
(%) (24.2) (21.6)
MCM-2
No of adequate samples 66 88 30
(%) (74.2) (75.9) (68.2)
Sensitivity 81.3% 63.2%
(95% CI) (54.4, 96.0) (38.4, 83.7)
Specificity 76.0% 89.9%
(95% CI) (61.8, 86.9) (80.2, 95.8)
NPV 92.7% 89.9%
Cytology
No of adequate samples 66 88
(%) (74.2) (75.9)
Sensitivity 62.5% 55.0%
(95% CI) (35.4, 84.8) (31.5, 76.9)
Specificity 75.5% 77.9%*
(95% CI) (61.1, 86.7) (66.2, 87.1)
NPV 90.2% 88.3%
MCM-2/cytology
No of adequate samples 66 89
(%) (74.2) (76.7)
Sensitivity 81.3% 65.0%
(95% CI) (54.4, 96.0) (40.8, 84.6)
Specificity 76.0% 88.4%
(95% CI) (61.8, 86.9) (78.4, 94.9)
NPV 92.7% 89.7%
Abbreviations: CI, confidence interval; CS, cystoscopic surveillance; GH, gross
haematuria; MCM-2, minichromosome maintenance protein-2; MH, microscopic
haematuria; NPV, negative predictive value. The threshold number of MCM-2-
positive cells was 50 for the GH group and 200 for the CS group. For all adequate
samples, the presence or absence of bladder cancer was established by cystoscopy/
biopsy. The combined MCM-2/cytology test was considered positive if either of the
individual tests was positive. *Po0.05 for MCM-2 testing vs urine cytology.
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95 1C for 45min. The sections were then allowed to cool to room
temperature before being placed in the automated stainer. Slides
were incubated for 5min with hydrogen peroxide solution (Dako
REAL S2023), to block endogenous peroxidase, then rinsed three
times in Dako REAL wash buffer (S3006). Primary antibody
MCM-2 (Scarpini et al, 2008), diluted 1 : 40 in antibody diluent
(Dako REAL S2022), was applied for 60min at room temperature
before being rinsed twice with wash buffer.
Pre-diluted peroxidase-polymer labelled goat anti-mouse/rabbit
secondary antibody detection reagent (Envision, Dako) was
applied for 30min at room temperature, followed by a further
wash with buffer. Sites of peroxidase activity were then demon-
strated with DAB, applied for two successive 5min periods. After a
rinse in water, slides were immersed in 0.5% copper sulphate in
saline stain enhancer for 5min. Following this, slides were lightly
counterstained in haematoxylin for 10 s then rinsed in tap water
before being ‘blued’ in Scott’s tap water substitute for 40 s. Slides
were then rinsed in water, dehydrated through graded alcohols to
xylene and cover slipped using mounting media.
The bladder cancer cell line EJ28 acted as a positive control for
MCM-2 staining. A duplicate negative control slide was run in
parallel, where the primary antibody was replaced by non-immune
mouse immunoglobulin (Dako Universal negative mouse control
N1695). The presence of MCM-2-positive staining of urothelial
cells in the cytology samples was assessed by the lead consultant
cytopathologist at Aberdeen Royal Infirmary (MM), who was
blinded to all clinical information. Representative images of EJ28
cells and a clinical sample are shown in Figure 1.
Slide Review
Cytology assessment The PAP-stained slides were examined to
provide a diagnosis based on cell morphology. Four diagnostic
categories were used, based on conventional terminology for
routine reporting of cytological specimens. The ‘atypical’ and
‘suspicious’ categories were combined and graded as ‘indetermi-
nate’. The other categories used were ‘benign’ and ‘malignant’. For
consistency with the ICC evaluation (see Results), a slide with a cell
count of fewer than 5000 urothelial cells was deemed inadequate,
unless the cells appeared malignant. Samples were also assessed
using a combination of cytology and MCM-2 ICC (see below) and
considered positive if either of the individual tests was positive.
Immunocytochemistry assessment Each slide was examined to
determine the total cell count and the number of MCM-2-positive
nuclei. A semi-quantitative total cell count was performed by
examining 10 high power fields (HPF;  40 objective lens) selected
at random from within the standard circular cell monolayer
generated by the Thinprep 2000 processor. The area of the
monolayer (always 20mm2) was divided by the area of an HPF, to
determine the number of HPFs per monolayer. The multiplication
factor for the microscope used in Aberdeen was 1072 but for
simplification 1000 was applied. This value was then multiplied by
the average number of cells per HPF, to determine the number of
cells per monolayer (slide). The same multiplication principle was
also used for the microscope in Manchester (where slides from
Cambridge study were evaluated). If the number of cells per HPF
was 45, the total cell count values derived were rounded into
categories, as follows: (i) Slides with 5–7 cells per HPF were
denoted to contain 5000 cells in total; (ii) slides with 8–12 cells per
HPF were denoted to contain 10 000 cells; (iii) slides with 13–17
cells per HPF were denoted to contain 15 000 cells; (iv) slides
with 18–24 cells per HPF were denoted to contain 20 000 cells;
(v) slides with 25–34 cells per HPF were denoted to contain 30 000
cells; (vi) slides with 35–44 cells per HPF were denoted to contain
40 000 cells, etc. Accordingly, the values of total cell count used
were: 1000, 2000, 3000, 4000, 5000, 10 000, 15 000, 20 000, 30 000,
40 000, and so on.
Counting of MCM-2-positive nuclei was done in a similar way,
providing the total MCM-2 count was greater than 1000, that is, at
least one positive nucleus per HPF. For slides with fewer positive
nuclei, half of the entire monolayer was examined and the count
was then doubled to indicate the number of cells per monolayer
Figure 1 Representative images from ICC staining. Expression of MCM-
2 (brown) in cells from the urine of a patient with bladder cancer (A) and
in the bladder cancer cell line EJ28 (B). Negative control EJ28 cells stained
with non-immune mouse immunoglobulin are shown in (C).
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(slide). This value was then rounded to the nearest 100 cells. If
there were fewer than 50 cells in half of the monolayer then the
whole monolayer was examined and all positive nuclei counted.
All counting procedures described above were established in the
initial studies at Aberdeen. An identical procedure was carried out
in Manchester Royal Infirmary for the validation study.
Quality assurance
In Aberdeen three members of the research team (BR, MM and JN)
reviewed the clinical and laboratory data for four groups of
participants, namely: randomly selected participants from the GH
and CS groups (n¼ 20); patients with histologically proven bladder
cancer (n¼ 34); patients whose outcomes were identified as
inconclusive (n¼ 50); and all normal controls (n¼ 50). The
essential data checked for accuracy were: participant number,
date of birth, cohort, tumour diagnosis including stage and grade,
MCM-2 ICC result and cytology result. The overall accuracy
ranged from 96–100%.
For the Cambridge study similar quality assurance was carried
out in the cytopathology laboratory at Addenbrooke’s Hospital, at
Quest Laboratories (for ICC) and by two independent cytopathol-
ogists at Manchester Royal Infirmary (for slide assessment).
Statistical analysis
The principal analysis was designed to assess the sensitivity and
specificity of MCM-2 cell count for detecting bladder cancer
diagnosed cystoscopy and biopsy. Analyses were carried out
separately for GH and CS patients at each centre. In the initial
study in Aberdeen, this was done for different thresholds of total
urothelial cell numbers, as well as numbers of MCM-2-positive
cells (using 10, 30, 50, 100, 200 and 400 positive cells). Confidence
intervals for sensitivity and specificity were calculated to indicate
error limits for full population estimation. In addition, for the
initial study (Aberdeen) receiver operating characteristics (ROC)
curves were plotted and used to determine an optimal intermediate
threshold that balanced levels of sensitivity and specificity.
For comparison, sensitivity and specificity analyses were also
performed using results from routine urine cytology, or from
the combination of MCM-2 and cytology. The values were
compared with those of MCM-2 ICC alone using the binomial
proportions test.
RESULTS
Initial study (Aberdeen)
In order to establish thresholds at which MCM-2 would be
considered positive, sensitivity and specificity for bladder cancer
were calculated using a range of cutoff points based on numbers of
MCM-2-positive cells per slide, as well as the total number of
urothelial cells present.
Receiver operating characteristics curves were generated from
different MCM-2 threshold values, using a minimum total cell
count of 5000 to define an adequate sample (Figure 2). The full list
of coordinates is provided in the Supplementary Data
(Supplementary Tables 1A and 1B). The total number of patients
with adequate samples for MCM-2 ICC was 313 (Table 1). For these
patients, there were 21 cases of bladder cancer in the GH group
(17.9% of the adequate samples), 5 (4.5%) in the CS group and
none in the MH group. Of the GH and CS samples, 230 were
adequate for cytology, while 231 were adequate for the combined
MCM-2 ICC/cytology test (Table 1).
For the GH samples that were adequate for MCM-2 ICC
(n¼ 117), the area under the ROC curve was 0.820, being different
from the random 0.5 level with significance Po0.0005. The best
compromise cutoff set at an MCM-2 count of 50 or more as a
positive. This yielded a sensitivity value of 85.7% (95% CI (63.7,
97.0)) and a specificity value of 52.1% (95% CI (41.6, 62.4))
(Figure 2). Using this threshold, the sensitivity of MCM-2 testing
increased with bladder cancer grade, being 75% for grade 1, 80%
for grade 2 and 100% for grade 3, although it should be noted that
numbers in each category were small (Supplementary Table 2).
Sensitivity for disease stage was 83% for pTa, 100% for pT1 and
67% for pT2 (Supplementary Table 2).
The sensitivity of urine cytology in the same GH group (treating
‘indeterminate’ as no diagnosis), was less than that of MCM-2 ICC,
at 71.4% (95% CI (47.8, 88.7)). However, urine cytology produced a
greater specificity, of 88.5% (95% CI (80.4, 94.10)), (Po0.005)
(Table 1). Sensitivity and specificity values for the combined test
(requiring positivity for MCM-2 ICC or cytology) were similar to
those for MCM-2 ICC alone (Table 1).
For the CS samples that were adequate for MCM-2 ICC
(n¼ 112), the area under the ROC curve was 0.821, which was
significantly different from the random 0.5 (P¼ 0.015). The best
compromise cutoff set an MCM-2 count of 200 or more as a
positive. This gave a specificity of 79.4% (95% CI (70.5, 86.6)) and
a sensitivity of 60% (95% CI (14.7, 94.7)). Using this threshold, the
sensitivity of MCM-2 testing increased with bladder cancer grade
(being 50% for grade 2 and 100% for grade 3) and stage (50% for
pTa, and 100% for pT2), although numbers in each category were
small (Supplementary Table 2).
The specificity of cytology in the same CS group was marginally
less than that of MCM-2 ICC, at 72.2% (95% CI (62.8, 80.4)),
although sensitivity of cytology was markedly lower, at 40% (95%
CI (5.3, 85.3)) (Table 1). Sensitivity and specificity values for the
combined test were similar to those for MCM-2 ICC alone
(Table 1).
Validation study (Cambridge)
In the validation study, we tested the optimal thresholds of total
cell number and number of MCM-2-positive cells that were
determined from the initial study. The total number of patients
with adequate samples for MCM-2 ICC was 184 (Table 2). For these
patients, there were 16 cases of bladder cancer in the GH group
(24.2% of the adequate samples), 19 (21.6%) in the CS group and
none in the MH group. Of the GH and CS samples, 154 were
adequate for cytology, while 155 were adequate for the combined
MCM-2 ICC/cytology test (Table 2).
For the GH samples that were adequate for MCM-2 ICC (n¼ 66),
applying the cutoff of 50 or more MCM-2-positive cells yielded a
sensitivity of 81.3% (95% CI (54.4, 96.0)), a negative-predictive
value (NPV) of 92.7% and a specificity of 76.0% (95% CI (61.8,
86.9). Sensitivities were 66.7% for grade 1, 75% for grade 2 and
87.5% for grade 3 disease, 100% for CIS; and 80% for pTa and
100% for pT1 tumours (Supplementary Table 3), although
numbers in each category were small.
The sensitivity of urine cytology in the same GH group (treating
‘indeterminate’ as no diagnosis), was lower, at 62.5% (95% CI
(35.4, 84.8)), although the difference was not significant
(P¼ 0.433). The specificity of urine cytology was similar to that
of MCM-2 ICC, at 75.5% (95% CI (61.1, 86.7)) (P¼ 0.95) (Table 2).
Sensitivity and specificity values for the combined test (requiring
positivity for MCM-2 ICC or cytology) were similar to those for
MCM-2 ICC alone (Table 2).
For the CS samples that were adequate for MCM-2 ICC (n¼ 88),
applying the cutoff of 200 or more MCM-2-positive cells gave a
specificity of 89.9% ((95% CI (80.2, 95.8)), a sensitivity of 63.2%
(95% CI (38.4, 83.7)) and a NPV of 89.9%. Sensitivities were 42.9%
for grade 1, 50% for grade 2 and 100% for grade 3 disease; and
56.3% for pTa and 100% for pT4 tumours, although numbers in
each category were small (Supplementary Table 3).
The specificity of cytology in the same CS group was
significantly less than that of MCM-2 ICC, at 77.9% (95% CI
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(66.2, 87.1)) (P¼ 0.05). The sensitivity of cytology was also less
than that of MCM-2 ICC, at 55.0% (95% CI (31.5, 76.9)) (Table 2).
Sensitivity and specificity values for the combined test were similar
to those for MCM-2 ICC alone (Table 2).
To extend the ROC analysis performed for the Aberdeen data,
ROC curves were also drawn for the MCM-2 ICC results from the
Cambridge study (Figure 2). For the GH results, the area under the
curve was 0.810, being different from the random 0.5 level with
significance Po0.0005. The best compromise cutoff was again at
50 MCM-2-positive cells. Similarly, for the CS data the area under
the curve was 0.728, being different from the random 0.5 level with
significance 0.002. The best compromise cutoff was again at 200
MCM-2-positive cells. The full list of coordinates is provided in
Supplementary Tables 1C and 1D, together with the two-way tables
for each cutoff point for the GH and CS groups.
DISCUSSION
Widespread population screening for bladder cancer is not feasible
or cost effective. However, focussing on individuals at high risk,
such as those with exposure to known carcinogens (cigarette
smoke, cyclophosphamide, pelvic radiation and those working in
the dye and leather industries), could be worthwhile. Flexible
cystoscopy is an integral part of the diagnosis and surveillance of
bladder cancer. An accurate biomarker may have the potential to
complement, delay or even replace cystoscopy in the monitoring
and diagnosis of patients with bladder cancer. Similarly, tumour
markers could also complement or replace urine cytology. In the
present study, we focussed on assessing the suitability of MCM-2
ICC for detecting bladder cancer in the largest sample set analysed
to date, rather than comparing different tests in fewer samples,
which would have given less definitive information on the
potential of the MCM-2 test.
We studied two main patient groups, in which there are different
priorities for the performance of a bladder cancer screening test. In
the GH group, high sensitivity is particularly important, while in
the CS group high specificity is needed, to avoid unnecessary
invasive procedures (Budman et al, 2008). Our initial study
showed that a threshold of 50 MCM-2-positive cells was optimal in
the GH group. In the validation study, this threshold provided a
sensitivity that was superior to urine cytology, with similar
specificity. In the CS group there was a different optimal threshold
of 200. In the validation study, this threshold provided signifi-
cantly higher specificity than urine cytology, together with a
marginal increase in sensitivity. These benefits are attributable to
the improved objectivity offered by MCM-2 ICC, as it is easier for
an observer to detect brown-stained nuclei than to evaluate more
subtle changes in cell size, shape, nuclear contour, and so on, as
required in the analysis of conventional cytology samples. There
was minimal benefit from combining MCM-2 ICC and cytology.
The numbers of malignant cases overall were too small to allow
meaningful logistic regression analysis to compare the perfor-
mance of MCM-2 ICC alone vs combined MCM-2 ICC and
cytology.
The MCM-2 ICC method that we evaluated is a first generation
approach, which is likely to evolve in the future. Importantly the
ICC slides were evaluated and cell counts determined by human
observers. In this setting, optimal discrimination between patients
with and without malignancy was provided by a minimal total cell
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Figure 2 Receiver operator characteristic curve analysis. The top row shows data for the initial study, while the bottom row shows data for the validation
study. The GH groups are shown in the left hand column, while the CS groups are in the right hand column. In all graphs, diagonal segments are produced
by ties.
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count of 5000 per slide, leading to relatively high overall
inadequacy rates. The present data warrant development of new
generation urine MCM-2 ICC tests, based on image analysis and
automated quantification of total cell counts and numbers of
immuno-positive cells. This approach is well suited to LBC
platforms, which enable automated slide assessment and multi-
parameter testing. Such objective analysis is likely to provide
greater discriminatory power than is provided by human
observations, so that lower overall cell numbers (and probably
lower MCM-2 thresholds) would be required, thereby increasing
sample adequacy. Indeed, given the considerable time and labour
required for human observers to assess slides for cell adequacy and
MCM-2 numbers, an automated platform for quantifying ICC-
stained slides is now an important requirement. Such a develop-
ment would parallel those of liquid-phase assays for bladder
cancer, where adequacy requirements improved from 6000 to 1500
MCM-positive cells as test methodology evolved (Stoeber et al,
1999; Stoeber et al, 2002).
The design of the present study only permitted limited
comparisons with other approaches to bladder cancer screening.
It will be important in future work to perform direct head to
head comparisons between MCM-2 ICC, cytology and other
biomarker-based tests, such as NMP22, UroVysion and so on
(Yutkin et al, 2010). Of principal interest will be the clinical
performance (sensitivity, specificity, predictive values, adequacy
rates and so on) of the tests, when used singly or in combination. It
will also be important to evaluate the practicability of each test and
the ease of adoption in clinical laboratories. Minichromosome
maintenance protein-2 ICC offers several advantages in this
regard. For example, the method of sample collection required is
straightforward, being identical to that already in use for obtaining
routine urine cytology samples. In addition, MCM-2 ICC signals
are suitable for automated detection in future iterations of the test,
while the test slides preserve intact cells, allowing morphological
information to be derived from the haematoxylin counterstain.
We conclude that MCM-2 ICC offers potential for accurate
detection of bladder cancer, in both GH and CS patient groups.
The test is well suited to automation and further iterations are
likely to improve sample adequacy, throughput and clinical
performance, either in isolation or in combination with other
biomarkers.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Baldwin P, Laskey R, Coleman N (2003) Translational approaches to
improving cervical screening. Nat Rev Cancer 3: 217–226
Budman LI, Kassouf W, Steinberg JR (2008) Biomarkers for detection and
surveillance of bladder cancer. Can Urol Assoc J 2: 212–221
Chatrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K,
Vowler SL, Grant JW, Saeed IT, Howard D, Laskey RA, Coleman
N (2003) Aberrant expression of minichromosome maintenance protein-
2 and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer 89:
1048–1054
Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey
RA, Miller R, Coleman N (2002) Analysis of minichromosome
maintenance proteins as a novel method for detection of colorectal
cancer in stool. Lancet 359: 1917–1919
Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH,
Coleman N (1999) Minichromosome maintenance proteins as biological
markers of dysplasia and malignancy. Clin Cancer Res 5: 2121–2132
Gonzalez MA, Tachibana KE, Laskey RA, Coleman N (2005) Control of
DNA replication and its potential clinical exploitation. Nat Rev Cancer 5:
135–141
Halling KC, Kipp BR (2008) Bladder cancer detection using FISH
(UroVysion assay). Adv Anat Pathol 15: 279–286
Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD,
Hawkins IR (1983) Superficial bladder cancer: progression and
recurrence. J Urol 130: 1083–1086
Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF (2008) Urine-
based biomarkers for the early detection and surveillance of non-muscle
invasive bladder cancer. Minerva Urol Nefrol 60: 217–235
Herr HW (1999) The natural history of a T1 bladder cancer: life-long
tumour diathesis. BJU Int 84: 1102–1103
Hwang EC, Choi HS, Jung SI, Kwon DD, Park K, Ryu SB, Use of the NMP22
(2011) BladderChek test in the diagnosis and follow-up of urothelial
cancer: a cross-sectional study. Urology 77: 154–159
Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-
carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H,
Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ,
Shariat SF (2006) Institutional variability in the accuracy of urinary
cytology for predicting recurrence of transitional cell carcinoma of the
bladder. BJU Int 97: 997–1001
Kearsey SE, Labib K (1998) MCM proteins: evolution, properties, and role
in DNA replication. Biochem Biophys Acta 1398: 113–136
Kearsey SE, Maiorano D, Holmes EC, Todorov IT (1996) The role of MCM
proteins in the cell cycle control of genome duplication. Bioessays 18:
183–190
Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H,
Thymara I, Thomas-tsagli E, Patsouris E (2005) Minichromosome
maintenance proteins 2 and 5 expression in muscle-invasive urothelial
cancer: a multivariate survival study including proliferation markers and
cell cycle regulators. Hum Pathol 36: 899–907
Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly
available bladder tumor markers vs cytology: results of a comprehensive
literature review and meta-analyses. Urology 61: 109–118; discussion 118
Madine MA, Swietlik M, Pelizon C, Romanowski P, Mills AD, Laskey RA
(2000) The roles of the MCM, ORC, and Cdc6 proteins in determining the
replication competence of chromatin in quiescent cells. J Struct Biol 129:
198–210
Maiorano D, Van Assendelft GB, Kearsey SE (1996) Fission yeast cdc21,
a member of the MCM protein family, is required for onset of S phase
and is located in the nucleus throughout the cell cycle. EMBO J 15:
861–872
Musahl C, Holthoff HP, Lesch R, Knippers R (1998) Stability of the
replicative Mcm3 protein in proliferating and differentiating human
cells. Exp Cell Res 241: 260–264
Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, Garbeglio
A (1991) Results of contemporary radical cystectomy for invasive
bladder cancer: a clinicopathological study with an emphasis on the
inadequacy of the tumor, nodes and metastases classification. J Urol 145:
45–50
Prout JR GR, Barton BA, Griffin PP, Friedell GH (1992) Treated history of
noninvasive grade 1 transitional cell carcinoma. The National Bladder
Cancer Group. J Urol 148: 1413–1419
Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, Duffy S, Ritchie G,
Kleijnen J, Westwood M (2006) Diagnostic tests and algorithms used in
the investigation of haematuria: systematic reviews and economic
evaluation. Health Technol Assess 10: iii–iv, xi-259
Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G (1988)
Natural history and treatment of low and high risk superficial bladder
tumors. J Urol 139: 283–285
Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N,
Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller
R, Nathan M, Coleman N (2008) Improved screening for anal neoplasia
by immunocytochemical detection of minichromosome maintenance
proteins. Cancer Epidemiol Biomarkers Prev 17: 2855–2864
Sirieix PS, O’donovan M, Brown J, Save V, Coleman N, Fitzgerald RC (2003)
Surface expression of minichromosome maintenance proteins provides a
novel method for detecting patients at risk for developing adenocarci-
noma in Barrett’s esophagus. Clin Cancer Res 9: 2560–2566
Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, Coleman N,
Bullock N, Laskey RA, Hales CN, Williams GH (1999) Immunoassay for
urothelial cancers that detects DNA replication protein Mcm5 in urine.
Lancet 354: 1524–1525
Stoeber K, Swinn R, Prevost AT, De Clive-lowe P, Halsall I, Dilworth SM,
Marr J, Turner WH, Bullock N, Doble A, Hales CN, Williams GH (2002)
Detection of bladder cancer by MCM-2 immunocytochemistry
K Saeb-Parsy et al
1390
British Journal of Cancer (2012) 107(8), 1384 – 1391 & 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
Diagnosis of genito-urinary tract cancer by detection of minichromosome
maintenance 5 protein in urine sediments. J Natl Cancer Inst 94: 1071–1079
Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L,
Williams ED, Williams GH (2001) DNA replication licensing and human
cell proliferation. J Cell Sci 114: 2027–2041
van der Poel HG, Debruyne FM (2001) Can biological markers replace
cystoscopy? An update. Curr Opin Urol 11: 503–509
Williams GH, Romanowski P, Morris L, Madine M, Mills AD, Stoeber K,
Marr J, Laskey RA, Coleman N (1998) Improved cervical smear
assessment using antibodies against proteins that regulate DNA
replication. Proc Natl Acad Sci USA 95: 14932–14937
Yutkin V, Nisman B, Pode D (2010) Can urinary biomarkers replace
cystoscopic examination in bladder cancer surveillance? Expert Rev
Anticancer Ther 10: 787–790
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the
license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
Detection of bladder cancer by MCM-2 immunocytochemistry
K Saeb-Parsy et al
1391
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(8), 1384 – 1391
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
